Real-World Effectiveness of Sitagliptin as Add-On Therapy in Patients With Type 2 Diabetes Mellitus

References

• . Yoon KH, Lee JH, Kim JW, . Epidemic obesity and type 2 diabetes in Asia. Lancet. 2006;368(9548):1681–1688
   PubMed Web of Science ®Google Scholar
• . International Diabetes Federation (IDF). Diabetes Atlas, 5th ed, 2011. http://www.idf.org/diabetesatlas/5e/the-global-burden. Accessed on May 1, 2013
   Google Scholar
• . Selvin E, Bolen S, Yeh HC, . Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med. 2008;168(19):2070–2080
   PubMedGoogle Scholar
• . American Diabetes Association. Standards of medical care in diabetes—2013. Diabetes Care. 2013;36( Suppl 1):S11–S66
   PubMed Web of Science ®Google Scholar
• . Inzucchi SE, Bergenstal RM, Buse JB, . Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Diabetes Care. 2012;35(6):1364–1379
   PubMed Web of Science ®Google Scholar
• . Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999;281(21):2005–2012
   PubMed Web of Science ®Google Scholar
• . Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA. 2002;287(3):360–372
   PubMed Web of Science ®Google Scholar
• . Lai MS, Chu CS, Lin SH, Lin MS. Prescribing patterns in primary health care in Taiwan. Int J Clin Pharmacol Ther. 1995;33(8):437–441
   PubMedGoogle Scholar
• . Simpson SH, Majumdar SR, Tsuyuki RT, Eurich DT, Johnson JA. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. Can Med Assoc J. 2006;174(2):169–174
   PubMed Web of Science ®Google Scholar
• . Monami M, Balzi D, Lamanna C, . Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality. Diabetes Metab Res Rev. 2007;23(6):479–484
   PubMed Web of Science ®Google Scholar
• . Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457–2471
   PubMed Web of Science ®Google Scholar
• . Azoulay L, Yin H, Filion KB, . The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ. 2012;344:e3645
   PubMed Web of Science ®Google Scholar
• . Lewis JD, Ferrara A, Peng T, . Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care. 2011;34(4):916–922
   PubMed Web of Science ®Google Scholar
• . Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696–1705
   PubMed Web of Science ®Google Scholar
• . Herman GA, Stein PP, Thornberry NA, Wagner JA. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin. Clin Pharmacol Ther. 2007;81(5):761–767
   PubMed Web of Science ®Google Scholar
• . Gallwitz B. Sitagliptin: profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes. Drugs Today. 2007;43(1):13–25
   PubMedGoogle Scholar
• . Aschner P, Katzeff HL, Guo H, . Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12(3):252–261
   PubMed Web of Science ®Google Scholar
• . Karasik A, Aschner P, Katzeff H, Davies MJ, Stein PP. Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials. Curr Med Res Opin. 2008;24(2):489–496
   PubMed Web of Science ®Google Scholar
• . Florentin M, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Sitagliptin in clinical practice: a new approach in the treatment of type 2 diabetes. Expert Opin Pharmacother. 2008;9(10):1705–1720
   PubMed Web of Science ®Google Scholar
• . Iwamoto Y, Tajima N, Kadowaki T, . Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial. Diabetes Obes Metab. 2010:12(7):613–622
   PubMedGoogle Scholar
• . Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP; Sitagliptin Study 024 Group, for the Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2007;9(2):194–205
   PubMed Web of Science ®Google Scholar
• . Seck T, Nauck M, Sheng D, . Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract. 2010;64(5):562–576
   PubMed Web of Science ®Google Scholar
• . Williams-Herman D, Engel SS, Round E, . Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC. 2010;10:7–27
   Google Scholar
• . Barzilai N, Guo H, Mahoney EM, . Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin. 2011;27(5):1049–1058
   PubMed Web of Science ®Google Scholar
• . McIntosh B, Cameron C, Singh SR, . Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis. Open Med. 2011;5(1):e35–e48
   PubMedGoogle Scholar
• . Nonaka K, Kakikawa T, Sato A, . Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract. 2008;79(2):291–298
   PubMed Web of Science ®Google Scholar
• . Mohan V, Yang W, Son HY, ; Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. Diabetes Res Clin Pract. 2009;83(1):106–116
   PubMed Web of Science ®Google Scholar
• . Oh TJ, Jung HS, Bae JH, . Clinical characteristics of the responders to dipeptidyl peptidase-4 inhibitors in Korean subjects with type 2 diabetes. J Korean Med Sci. 2013;28(6):881–887
   PubMedGoogle Scholar
• . Reasner C, Olansky L, Seck TL, . The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2011;13(7):644–652
   PubMed Web of Science ®Google Scholar
• . Chien MN, Lee CC, Chen WC, . Effect of sitagliptin as add-on therapy in elderly type 2 diabetes patients with inadequate glycemic control in Taiwan. Int J Gerontol. 2011;5(2):103–106
   Web of Science ®Google Scholar
• . Mudaliar S, Henry RR. Incretin therapies: effects beyond glycemic control. Am J Med. 2009;122(6):S25–S36
   Google Scholar
• . Holst JJ, Burcelin R, Nathanson E. Neuroprotective properties of GLP-1: theoretical and practical applications. Curr Med Res Opin. 2011;27(3):547–558
   PubMed Web of Science ®Google Scholar
• . Williams-Herman D, Xu L, Teng R, . Effect of initial combination therapy with sitagliptin and metformin on β-cell function in patients with type 2 diabetes. Diabetes Obes Metab. 2012;14(1):67–76
   PubMedGoogle Scholar
• . Stratton IM, Adler AI, Neil HAW, . Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–412
   PubMed Web of Science ®Google Scholar
• . Yu NC, Su HY, Chiou ST, . Trends of ABC control 2006–2011: A national survey of diabetes health promotion institutes in Taiwan diabetes research and clinical practice. Diabetes Res Clin Pract. 2013;99(2):112–119
   PubMedGoogle Scholar